Aurobindo Pharma Intrinsic Value
Aurobindo Pharma (AUROPHARMA) median intrinsic value is ₹3064.00 from 9 valuation models (range ₹460–₹3830), vs current price ₹1532.00 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Read Aurobindo Pharma dividend policy for the complete payout history and dividend yield track record.
AUROPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Aurobindo Pharma intrinsic value across 9 models vs current price ₹1532.00 — upside/downside and value range per method. Analyse Aurobindo Pharma shareholding analysis to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1395.68 | ₹1116.54 - ₹1674.82 | -8.9% | EPS: ₹63.44, Sector P/E: 22x |
| Book Value Method | asset | ₹3830.00 | ₹3447.00 - ₹4213.00 | +150.0% | Book Value/Share: ₹6532.93, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3064.00 | ₹2757.60 - ₹3370.40 | +100.0% | Revenue/Share: ₹6116.55, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3064.00 | ₹2757.60 - ₹3370.40 | +100.0% | EBITDA: ₹7064.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3830.00 | ₹3064.00 - ₹4596.00 | +150.0% | CF Growth: 4.2%, Discount: 15% |
| PEG Ratio Method | growth | ₹459.60 | ₹413.64 - ₹505.56 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹980.15 | ₹882.13 - ₹1078.16 | -36.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹3064.00 | ₹2757.60 - ₹3370.40 | +100.0% | ROE: 9.7%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹3053.70 | ₹2748.33 - ₹3359.07 | +99.3% | EPS: ₹63.44, BVPS: ₹6532.93 |
AUROPHARMA Intrinsic Value vs Market Price — All Valuation Models
Aurobindo Pharma fair value range ₹460–₹3830 vs current market price ₹1532.00 across 9 valuation models. For current market price and key ratios, visit AUROPHARMA share price screener.
AUROPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Aurobindo Pharma median intrinsic value ₹3064.00, current price ₹1532.00 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of AUROPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Aurobindo Pharma (AUROPHARMA) is ₹3064.00 (median value). With the current market price of ₹1532.00, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹459.60 to ₹3830.00, indicating ₹459.60 - ₹3830.00.
Is AUROPHARMA undervalued or overvalued?
Based on our multi-method analysis, Aurobindo Pharma (AUROPHARMA) appears to be trading below calculated value by approximately 100.0%.
AUROPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Aurobindo Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 12.68 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 9.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.61x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
AUROPHARMA Cash Flow Quality — Operating & Free Cash Flow
Aurobindo Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3,925 Cr | ₹2,992 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹2,435 Cr | ₹314 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹2,387 Cr | ₹402 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹5,017 Cr | ₹3,412 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹3,329 Cr | ₹3,329 Cr | Positive Free Cash Flow | 8/10 |